EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO argues, since payers will still be under pressure.
You may also be interested in...
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
The Chinese company's R&D leader discusses the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.
Sorrento plans to meet with the US FDA regarding abivertinib, but the agency’s tough stance on drug approvals based on single-country studies could thwart the company’s efforts.